Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2024 08:15 ET | Source: Senti Biosciences, Inc.

Senti Bio to Participate in Upcoming Investor Conferences

Senti Bio will participate in two upcoming investor conferences in September.
August 13, 2024 16:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
May 13, 2024 08:15 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
May 09, 2024 16:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
April 30, 2024 08:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.
March 21, 2024 16:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated...